Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | BCL2 | P10415 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 4/20 | 0.41 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941016 | 0.84 | CNR1 (0.46) | HRH3CYP2D6DYRK1AHTR3A | |
| SCHEMBL1939994 | 0.84 | HTR3A (0.53) | HRH3CYP2D6DYRK1AHTR3AMCHR1 | |
| SCHEMBL1942089 | 0.83 | CNR2 (0.45) | HRH3CYP2D6DYRK1AHTR3A | |
| SCHEMBL1939452 | 0.80 | HRH3 (0.43) | HRH3CYP2D6DYRK1AHTR3AIGF1R | |
| SCHEMBL1940284 | 0.80 | HRH3 (0.43) | HRH3CYP2D6DYRK1AHTR3AIGF1R | |
| SCHEMBL1941007 | 0.80 | CNR2 (0.48) | HRH3MCHR1KCNH2KDM4ESMN1; SMN2 | |
| SCHEMBL1940935 | 0.79 | CA12 (0.44) | HRH3CYP2D6DYRK1A | |
| SCHEMBL15615103 | 0.76 | MAOB (0.43) | MDM2MCHR1KCNH2IGF1RFDFT1 | |
| SCHEMBL1131017 | 0.73 | MDM2 (0.43) | MDM2HRH3CYP2D6MCHR1KCNH2 | |
| SCHEMBL1940172 | 0.73 | CTSV (0.46) | HRH3CYP2D6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173679-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2012-05-08 | — | — | US | disclosed |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2011-09-29 | — | — | US | disclosed |
| CN-101080395-B | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | THERAMEX SAM LAB | 2011-08-17 | — | — | CN | disclosed |
| US-7977364-B2 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERMAMEX (MC) | 2011-07-12 | — | — | US | disclosed |
| EP-1812404-B1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | THERAMEX (MC) | 2011-06-15 | — | — | EP | disclosed |
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | LABORATOIRE THERAMEX (FR) | 2009-01-22 | — | — | US | disclosed |
| CN-101080395-A | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | THERAMEX (MC) | 2007-11-28 | — | — | CN | disclosed |
| EP-1812404-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006040351-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | LABORATOIRE THERAMEX (MC) | 2006-04-20 | — | — | WO | disclosed |
| EP-1647549-A1 | Indazoles, benzisoxazoles and benzisothiazoles as estrogenic agents | LABORATOIRE THERAMEX (MC) | 2006-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023779-A1 | Indazoles, benzisoxazoles and benzisothiazoles and their use as estrogenic agents | ESR1, ESR2, GPER1 | KHK 2477/4885MDM2 891/4885HRH3 577/4885 |
| US-20110237624-A1 | INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AND THEIR USE AS ESTROGENIC AGENTS | ESR1, ESR2, GPER1 | KHK 2477/4885MDM2 891/4885HRH3 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.